Abstract:
OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of all the children and adolescents treated with atomoxetine at a university clinic in Catania, Italy, over a 3-year period were examined. A total of 55 clinically referred children and adolescents (aged 5-15 years, 53 males) with ADHD were treated with atomoxetine (10-110 mg/day; mean: 1.28 mg/kg/day) for a period ranging from 2 to 168 weeks (mean: 57.3 ± SD 39.4, median: 56). The IQ was assessed as part of the diagnostic evaluation prior to starting treatment. During treatment, clinical outcome was rated on the Clinical Global Impression-Improvement (CGI-I) and CGI-Severity (CGI-S) scales. RESULTS:The IQ ranged from 43 to 117 (mean: 80.6 ± SD 18.6, median: 84). The IQ and final CGI-I scores were negatively correlated (r = -0.68; p < 0.01). Children and adolescents with an IQ <85 were less likely to be responders (defined as a final CGI-I score of 1 or 2) than children and adolescents with an IQ ≥85 (20.71% vs 76.9%; p < 0.001). None of the patients discontinued atomoxetine due to adverse effects, while treatment was discontinued in 20 subjects due to a lack of efficacy or ambivalence of parents about pharmacological treatment. CONCLUSIONS:Atomoxetine appears to be less effective in children and adolescents with an IQ <85 than in children and adolescents in the average range of cognitive functioning. This difference is not accounted for by differences in the severity of ADHD symptoms, co-morbidity or reduced tolerability to the medication. These findings suggest that, in order to be fully informative, clinical trials of medications for ADHD should also include children and adolescents functioning in the borderline and cognitive disability range.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Mazzone L,Reale L,Mannino V,Cocuzza M,Vitiello Bdoi
10.2165/11590450-000000000-00000subject
Has Abstractpub_date
2011-06-01 00:00:00pages
503-9issue
6eissn
1172-7047issn
1179-1934pii
5journal_volume
25pub_type
杂志文章相关文献
CNS DRUGS文献大全abstract::Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prev...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0110-x
更新日期:2013-10-01 00:00:00
abstract::The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-018-0517-5
更新日期:2018-04-01 00:00:00
abstract:SYNOPSIS:Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors becaus...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-199605050-00007
更新日期:1996-05-01 00:00:00
abstract:BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-017-0421-4
更新日期:2017-04-01 00:00:00
abstract::Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923030-00003
更新日期:2009-01-01 00:00:00
abstract::Duloxetine (Cymbalta) is an orally administered, selective serotonin and noradrenaline reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive disorder (MDD). Based on a considerable body of evidence, duloxetine at dosages ranging from 40 to 120 mg/day was effective in the short- and lon...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200721070-00004
更新日期:2007-01-01 00:00:00
abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00766-w
更新日期:2020-11-01 00:00:00
abstract::At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620060-00005
更新日期:2006-01-01 00:00:00
abstract::Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...
journal_title:CNS drugs
pub_type: 评论,杂志文章
doi:10.2165/00023210-200822030-00006
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND:Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson's disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended-release (ER) capsule...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-018-0498-4
更新日期:2018-04-01 00:00:00
abstract:OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-014-0165-3
更新日期:2014-07-01 00:00:00
abstract::Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0299-y
更新日期:2016-01-01 00:00:00
abstract::Social anxiety disorder (SAD) is a prevalent and disabling disorder associated with significant co-morbidity. An increased awareness of SAD over the past two decades has given impetus to advances in the pharmacotherapeutic and psychotherapeutic treatment options for this disorder. On the basis of consistent data from ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200519050-00002
更新日期:2005-01-01 00:00:00
abstract:BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0102-x
更新日期:2013-11-01 00:00:00
abstract::In recent years, several new antiepileptic drugs (AEDs) have been licensed: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. These drugs have proven efficacy as add-on therapy in patients with difficult-to-treat partial epilepsy, as 20-50% of patients ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317060-00003
更新日期:2003-01-01 00:00:00
abstract::There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620010-00001
更新日期:2006-01-01 00:00:00
abstract:UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115030-00006
更新日期:2001-01-01 00:00:00
abstract::Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200822060-00002
更新日期:2008-01-01 00:00:00
abstract::The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-018-0548-y
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0049-y
更新日期:2013-04-01 00:00:00
abstract::Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11202620-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Admi...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-014-0147-5
更新日期:2014-05-01 00:00:00
abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0301-8
更新日期:2015-12-01 00:00:00
abstract::Cytomegalovirus (CMV) infection of the CNS occurs most commonly in patients with severe immunosuppression such as those with advanced HIV infection (i.e. AIDS) or those who have undergone bone marrow or solid organ transplantation. Immunocompetent patients are affected very rarely. The infection of the CNS may affect ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216050-00003
更新日期:2002-01-01 00:00:00
abstract::The common strategy to treat a migraine attack as soon as it begins, made for classical acute antimigraine treatments such as ergotamine and analgesics, has not been transposed to the triptans. The recommendation to delay triptan intake until headache intensity is at least moderate is merely a habit generated by the p...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-200115080-00001
更新日期:2001-01-01 00:00:00
abstract:PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-015-0229-z
更新日期:2015-02-01 00:00:00
abstract:OBJECTIVE:To collect descriptive data on the treatment of Alzheimer's disease with galantamine under naturalistic conditions. STUDY DESIGN:This was a prospective, open-label, observational study. PATIENTS:Subjects (n = 345) with mild to moderately severe dementia of the Alzheimer's type were recruited from 48 hospita...
journal_title:CNS drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00023210-200620110-00006
更新日期:2006-01-01 00:00:00
abstract::As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication through...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620100-00001
更新日期:2006-01-01 00:00:00
abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115050-00001
更新日期:2001-01-01 00:00:00
abstract::Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317070-00004
更新日期:2003-01-01 00:00:00